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Abstract
Chronic constipation, a common condition, can have remarkably negative 
effects on a patient’s quality of life. Recent research has identified factors that may 
influence the prognosis of chronic constipation and suggests the need for adequate 
therapy. However, the major obstacles in this field were: (1) a small number of 
therapeutic options, (2) no clear diagnostic criteria, and (3) no effective method to 
collect information form the patients. These were due to the fact that bowel move-
ment patterns vary widely among individuals, and also the functional constipation, 
including irritable bowel syndrome, is difficult to be distinguished from the chronic 
constipation. Recently, it has been demonstrated that the Rome IV diagnostic 
criteria of functional constipation and the Bristol stool form scale are useful for the 
objective evaluation and recording of stool. Based on these developments, and the 
increase of newly developed medicines the therapy for the constipation is signifi-
cantly changing and therefore, if conventional therapy for chronic constipation is 
ineffective, switching of medicines is possible. Therefore, clinicians should update 
the information of these newly developed drugs available in clinics and diagnostic 
criteria. For this purpose, in this chapter, we have summarized the perspective on 
the current paradigm of treatment for chronic constipation focusing on recently 
introduced therapeutic drugs.
Keywords: chronic constipation, Rome IV diagnostic criteria, secretagogues, 
lubiprostone
1. Introduction
Many reports describe a high prevalence of constipation worldwide. For exam-
ple, a survey conducted in North America by Higgins et al. reported prevalence 
rates of 12–19%, particularly among older populations [1]. Generally, research sug-
gests that constipation reduces the patient’s quality of life (QOL) to a level compa-
rable with the negative effects of allergy or inflammatory bowel disease [2]. Despite 
these negative characteristics, however, a clear overview of chronic constipation has 
not yet been established.
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The Rome IV diagnostic criteria, which were revised in 2016, are often used to 
evaluate functional constipation. However, these diagnostic criteria exclude irritable 
bowel syndrome (IBS), a prevalent condition (7–21%) that exists on a continuous 
spectrum with functional constipation. Notably, IBS and functional constipation 
may be associated with predominant symptoms such as abdominal pain or bloat-
ing, which are not necessarily predominant in all cases of constipation [3]. This 
suggests that IBS and functional constipation often overlap in real-world scenarios 
[4]. Furthermore, the diagnosis of chronic constipation, which often involves the 
appraisal of symptoms (including QOL measures), and associated therapies appear 
to be incomplete.
In addition to the lack of diagnostic and treatment methodology, the Japan 
Collaborative Cohort Study found evidence suggesting that a low bowel movement 
frequency increases the risks of cardiovascular disease (CVD), such as stroke and 
ischemic myocardial infarction, and of related mortality. The same study also found 
a high incidence of CVD among laxative users in Japan [5, 6]. Therefore, the effect 
of constipation indicates an increasingly poor prognosis. In this chapter, we review 
the present clinical practices targeting constipation and discuss newly introduced 
therapeutic drugs for constipation, such as secretagogues, which have recently 
yielded medical advances. With this review, we aim to prevent a perspective on the 
future treatment of chronic constipation.
2. Definition of constipation
Individual bowel movement patterns (including constipation) vary widely 
and are easily affected by many factors, including changes in the diet, living 
environment, mental status, and time course [7, 8]. Additionally, physicians and 
patients may hold different understandings of constipation. Consequently, the 
term “constipation” may encompass a broad spectrum of symptoms and situ-
ations. Despite these differences, constipation can be adequately defined as a 
status in which comfortable defecation is impossible, in accordance with many 
international clinical practice guidelines and review articles, as well as the Rome 
IV criteria [4, 9, 10].
3. Chronic constipation, including chronic functional constipation  
and IBS
Constipation can be roughly classified as acute or chronic, each of which can be 
further divided according to an organized or functional pathogenic mechanism. 
However, this chapter will discuss specifically chronic functional constipation in 
adult patients and its deleterious effects on the long-term QOL. Previously, the 
Rome III criteria were used to diagnose chronic functional constipation when a 
stringent definition is required for research purposes. In May 2016, however, the 
revised Rome IV criteria were published [10] (Table 1). Notably, these updated 
criteria include the requirement of other symptoms associated with difficulty of 
defecation and incompleteness of evacuation, as well as symptoms associated with 
constipation, and do not diagnose chronic functional constipation based on the 
frequency of bowel movements alone. Of note, these criteria require the exclusion 
of IBS prior to a diagnosis of chronic functional constipation (Table 2). However, 
this condition overlaps with IBS in many clinical cases. Accordingly, we recom-
mend that in actual clinical settings, cases in which a patient’s continued inability 
to defecate comfortably that has deleterious effects on daily life should be managed 
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as chronic constipation, even if the Rome IV criteria are not fulfilled [4]. Later, we 
discuss the diagnosis and management of chronic constipation, including chronic 
functional constipation and IBS.
3.1 Alarming symptoms associated with chronic constipation
Particular attention should be given to the management of constipation associ-
ated with alarming symptoms, which may correlate with a poor outcome due to the 
required therapy for an underlying disease or surgically treated condition. Patients 
with alarming symptoms should be further scrutinized and subjected to additional 
diagnostic testing before treatment is administered for constipation. Potentially 
alarming symptoms may include a change in stool caliber, heme-positive stool, 
iron-deficiency anemia, obstructive symptoms, an age of >50 years with no his-
tory of colon cancer screening, recent onset of constipation, rectal bleeding, rectal 
prolapse, and weight loss [9–11]. Such symptoms should be considered an indica-
tion for colonoscopy.
3.2 Secondary constipation
Secondary constipation should be excluded prior to a diagnosis of functional 
or chronic constipation due to IBS, as underlying high-risk diseases and etiologies 
must be identified [4, 10, 11]. Secondary constipation can be subdivided coarsely 
into drug-induced and symptomatic cases. Consequently, a diagnostic interview for 
chronic constipation should inquire about the time of onset, duration of disease, 
frequency of bowel movements, consistency of stool, symptoms associated with 
Diagnostic criteriaa for functional constipation (FC)
1. Must include 2 or more of the following:b
a. Straining during more than one-fourth (25%) of defecations
b. Lumpy or hard stools (Bristol Stool Form Scale: BSFS 1-2) more than one-fourth (25%) of defecations
c. Sensation of incomplete evacuation more than one-fourth (25%) of defecations
d. Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations
e. Manual maneuvers to facilitate more than one fourth (25%) of defecations (e.g., digital evacuation, 
support of the pelvic floor)
f. Fewer than 3 spontaneous bowel movements per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for irritable bowel syndrome
aCriteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
bFor research studies, patients meeting criteria for Opioid-Induced Constipation (OIC) should not be given a diagnosis 
of FC because it is difficult to distinguish between opioid side effects and other causes of constipation. However, 
clinicians recognize that these 2 conditions might overlap.
Table 1. 
The diagnostic criteria for functional constipation: This criteria is cited from “Mearin et al. [10]”.
Diagnostic criteriaa for irritable bowel syndrome
Recurrent abdominal pain, on average, at least a day per week in the last 3 months, associated with 2 or more of 
the following criteria:
1. Related to defecation
2. Associated with a change in frequency of stool
3. Associated with a change in form (appearance) of stool
aCriteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
Table 2. 
The diagnostic criteria for irritable bowel syndrome: This criteria is cited from “Mearin, et al. [10]”.
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constipation, and the presence of concrete situations of dyschezia (e.g., abdominal 
pain and/or bloating, sensation of incomplete evacuation, need for manual maneu-
vers to facilitate defecation, and evacuation time). A clinical history, including 
lifestyle factors and dietary fiber and fluid intake, should also be taken. A systemic 
physical examination that includes a digital rectal examination (palpation for 
gastrointestinal mass, anorectal inspection to assess fecal impaction, stricture, rectal 
prolapse, rectocele, paradoxical or nonrelaxing puborectalis activity, and rectal 
mass), laboratory analyses (complete blood counts, biochemical profile, calcium 
and glucose levels, and thyroid function tests) and colonoscopy is also required to 
exclude secondary constipation. In summary, underlying diseases and drug-affected 
constipation should be considered in an evaluation of chronic constipation.
3.2.1 Underlying diseases
The diagnosis and treatment of underlying diseases is very important in the 
management of chronic constipation. Underlying diseases that may cause chronic 
constipation are listed below [9]:
Mechanical obstruction: colorectal tumor, diverticulosis, stricture, external 
compression from tumor/other structures, large rectocele, megacolon, postopera-
tive abnormalities, and anal fissure.
Neurological disorders/neuropathy: autonomic neuropathy, cerebrovascular 
disease, cognitive impairment/dementia, depression, multiple sclerosis, Parkinson’s 
disease, and spinal cord pathology.
Endocrine/metabolic conditions: chronic kidney disease (CKD), dehydration, 
diabetes mellitus, heavy metal poisoning, hypercalcemia, hypermagnesemia, 
hyperparathyroidism, hypokalemia, hypomagnesemia, hypothyroidism, multiple 
endocrine neoplasia II, and porphyria.
Gastrointestinal disorders and local painful conditions: IBS, abscess, anal fissure, 
fistula, hemorrhoids, levator ani syndrome, megacolon, proctalgia fugax, rectal 
prolapse, rectocele, and volvulus.
Myopathies: amyloidosis, dermatomyositis, scleroderma, and systemic sclerosis.
Dietary causes: dieting, fluid depletion, low fiber intake, anorexia, dementia, and 
depression.
Other causes: cardiac disease, degenerative joint disease, and immobility.
3.2.2 Drug-induced constipation
When evaluating a case of chronic constipation, the patient’s current profile of 
medicine use must be understood precisely and considered during further treat-
ment. A list of drugs that may cause chronic constipation is provided below [9].
Prescription drugs: antidepressants, antiepileptics, antihistamines, antiparkinson 
drugs, antipsychotics, antispasmodics, calcium channel blockers, diuretics, mono-
amine oxidase inhibitors, opiates, sympathomimetics, tricyclic antidepressants, and 
statins.
Self-medication (i.e., over-the-counter drugs): antacids (containing aluminum and 
calcium), antidiarrheal agents, calcium and iron supplements, and nonsteroidal 
anti-inflammatory drugs.
4. Diagnostic approaches to the treatment of chronic constipation
An interview based on the diagnostic criteria (Table 1) for functional consti-
pation is useful when planning treatment for chronic constipation. The simple 
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and objective Bristol stool form scale, which is used worldwide, is particularly 
useful for enabling an evaluation and record of the stool form and thus elucidat-
ing an individual patient’s defecation status [12, 13]. When possible, the patient 
should maintain a stool diary that includes the number of bowel movements per 
day and stool consistency (Bristol stool form types 1–7, Figure 1) for approxi-
mately 1 week. This record is also useful for evaluating symptoms and sensations 
(e.g., sensation of incomplete evacuation, abdominal pain, and/or bloating) after 
evacuation [4].
The Bristol scale can also be used to estimate the colonic transit time. 
Currently, cases of functional constipation are categorized as normal-transit, 
slow-transit, or defecatory rectal evacuation disorder [10]. A previous histologi-
cal analysis reported that slow-transit constipation results from a reduction in 
Cajal cells [14], suggesting that this type is caused by a decrease in the statuses of 
lower postprandial phasic responses (e.g., the disappearance of bowel peristalsis) 
[15]. Other research indicates that defecatory rectal evacuation disorders are 
caused by functional failures (e.g., pelvic floor line coordination disturbance) 
[16]. Although Bristol stool form types 1 and 2 can be attributed to slower transit 
constipation and types 6 and 7 are characteristic of rapid transit constipation 
[17], patients who meet the diagnostic criteria for functional constipation often 
exhibit characteristics of slow colonic transit constipation [18]. Still, the diagnosis 
of defecatory rectal evacuation disorders does not require diagnostic colonic and 
anorectal testing [19].
An improved QOL is among the most important goals of treatment for chronic 
constipation. Accordingly, various questionnaires are useful during the processes of 
diagnosis and treatment (see Section 5). If initial conservative medical management 
does not cure chronic constipation, additional measures such as the balloon expul-
sion test [8, 20, 21], manometric assessment [20], defecography [22], and radio-
opaque marker testing of the whole-gut transit time should be considered [23]. 
Additional tests may also be performed, although the availability may be limited to 
certain medical centers or countries. Accordingly, interinstitutional cooperation is 
important.
Figure 1. 
The Bristol Stool Form Scale: This scale is a useful tool to evaluate stool and can evaluate colonic transit time
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5. Self-reported questionnaires for diagnostic purposes
Questionnaire-based self-report measures can be classified by the type of QOL 
evaluation and type of constipation severity quantitation. Various methods are 
currently advocated, although further progress in this area is needed [24]. The 
questionnaires most frequently mentioned in a literature search via the PubMed 
database are shown below.
5.1 Evaluation of severity of constipation
Constipation scoring system (CSS) [25]. The CSS comprises eight questionnaire 
items to assess the frequency of bowel movements, difficult or painful evacuation, 
completeness of evacuation, abdominal pain, time per attempt, type of assistance 
(including laxatives, digitation, or enemas), number of unsuccessful attempts 
at evacuation in a 24-h period, and duration of constipation. All but one item are 
scored on a 5-point Likert scale (range: 0–4); the type of assistance, including 
laxatives, is scored on a 3-point scale (range: 0–2). A cutoff score of 15 is used to 
indicate constipation.
Patient assessment of constipation symptoms (PAC-SYM) [26]. The PAC-SYM was 
validated for the assessment of chronic functional constipation in 216 adult patients 
in the USA. This tool includes 12 items to assess abdominal, rectal, and stool fac-
tors. The items are scored on a 5-point Likert scale (range: 0–4), with a score of 4 
indicating the worst symptom severity. The total possible scores for the PAC-SYM 
range from 0 to 48, and no diagnostic cutoff score has been reported. This question-
naire has a 7-point Likert scale for four items of abdominal symptoms and three 
items of rectal symptoms (e.g., abdominal pain, bloating, and rectal burning) from 
no discomfort to very severe discomfort.
5.2 QOL evaluation tool
Gastrointestinal symptom rating scale (GSRS) [27]. The GSRS is a questionnaire 
comprising 15 items intended to address common gastrointestinal symptoms. The 
scale can be completed by the patient within approximately 5 min, and the items are 
scored on a 7-point Likert scale ranging from no discomfort to very severe discom-
fort. For evaluation purposes, a mean scale score is calculated for the equivalent of 
items (e.g., heart burn, nausea, and abdominal pain), and a high score indicates 
more severe symptoms.
Patient assessment of constipation quality of life (PAC-QOL) [28]. The PAC-QOL 
is a simple self-reported questionnaire used to measure the patient’s QOL associated 
with constipation, including daily behavioral and therapeutic aspects relevant to 
constipation during the previous 2 week period. The PAC-QOL comprises 28 items 
divided into four subscales that address the patient’s worries/concerns relevant to 
constipation, physical discomfort, psychosocial discomfort, and satisfaction. The 
items are scored on a 5-point scale, and a higher score indicates a lower QOL. The 
original edition was developed in English and has since been translated into many 
languages.
6. Practical treatment
In this section, we aim to provide an overview of the various available treat-
ments for chronic constipation for which the details have been published. Patient 
education is a very important first step in the therapeutic management of chronic 
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constipation [3]. Patients should be instructed to consume an adequate quantity of 
dietary fiber (total fiber intake: 20–30 g/day), set a routine of regular toilet time 
after mealtimes, and take an on-defecation position involving elevation of the lower 
limbs. If such measures are ineffective, an oral fiber supplement, such as psyllium 
(up to 30 mg/day in divided doses) may be attempted [29].
Drug therapy should be initiated if the above-described lifestyle modifications 
fail to treat chronic constipation, and this should be accompanied by an assess-
ment of bowel movements every 2–4 weeks to determine the therapeutic effects. 
Generally, osmotic laxatives (e.g., lactulose, lactitol, mannitol, and sorbitol) are 
administered initially as these are cost-effective and have few adverse effects [18, 
30]. Although saline laxatives (e.g., magnesium sulfate) are frequently admin-
istered in Japan, these drugs are not widely accepted worldwide and have only 
been evaluated clinically in small-scale randomized controlled trials (RCTs) [31]. 
Furthermore, patients with renal failure face the risk of serious hypermagnesemia 
consequent to the use of magnesium sulfate [32]. However, this drug should be con-
sidered, given its low cost and abundant use in Japan. Polyethylene glycol laxatives 
(17–34 g/day) should also be considered, as many RCTs have indicated that these 
agents are more effective than lactulose [33, 34].
If chronic constipation remains unresolved by the above therapies, newer 
medicines should be considered. Recent years have seen the rapid development of 
novel agents such as secretagogues (e.g., lubiprostone and linaclotide). However, 
as the availability and indications of these new drugs for chronic constipation vary 
among countries, all medical treatment for chronic constipation should comply 
with national clinical practice guidelines or guiding principle. Finally, surgical or 
biofeedback treatment should be considered for cases of chronic constipation that 
cannot be resolved with medication and patients with defecatory rectal evacuation 
disorders [35, 36].
7. New therapeutic drugs for chronic constipation
The extensive development of novel drugs for chronic constipation has led to 
variability in the potential applications among countries. For example, neither 
secretagogues (e.g., plecanatide) nor serotonergic enterokinetic agents (e.g., 
prucalopride and selective 5-hydroxytryptamine receptor agonists) have been 
approved for use in Japan. Below, we comment mainly on the new therapeutic drugs 
for chronic constipation that have been authorized for use in Japan.
7.1 Lubiprostone
Various studies have analyzed lubiprostone, the most well-developed one of the 
newer class of drugs. The mechanism of action of this constipation-targeting drug 
is interesting. Lubiprostone is a selective type-2 chloride channel (ClC-2 channel) 
activator. This biogenic bicyclic fatty acid was developed by Cuppoletti and Ueno 
for the treatment of chronic constipation and has been approved for use worldwide 
after the initial authorization for manufacturing and marketing in the US and 
Japan. [37, 38] Lubiprostone is the first clinically applied secretagogue, and accord-
ingly, a broad range of clinical experience is associated with this drug. Moreover, the 
mechanism of action of this drug has been analyzed in much greater detail relative 
to secretagogues introduced subsequently. Specifically, this drug activates ClC-2 
channels expressed in the apical membranes of intestinal epithelial cells and exerts 
its laxative function by inducing the secretion of intestinal fluids. The ability of 
lubiprostone to improve constipation symptoms has been validated through RCTs 
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[39], which reported the maintenance of efficacy throughout a 48-week adminis-
tration period with no significant side effects [40].
Lubiprostone promotes the secretion of intestinal fluid by activating ClC-2 channels. 
Upon absorption from the small intestine, lubiprostone is degraded immediately to 
an inactive metabolite. Therefore, the effects of this drug are tissue selective, and 
few side effects have been observed. In the small intestine, lubiprostone activates 
the ClC-2 channels expressed on mucosal epithelial cells to promote the transport 
of chloride ions from the visceral lumen and concomitant countertransport of 
cations into the lumen. This activity induces a difference in the local osmotic pres-
sure across the epithelial cell membrane, and the resulting secretion of intestinal 
fluid expedites defecation [41, 42]. As the expression of the ClC-2 channel is not 
expected to vary according to age, sex, or race, lubiprostone may be effective in 
elderly patients with constipation.
Clinical usefulness of lubiprostone for chronic constipation. As mentioned above, 
multiple RCTs have validated the effectiveness of lubiprostone for chronic con-
stipation [39] and demonstrated a both sustained efficacy and a lack of serious 
adverse effects during a 48-week period of administration. The most common side 
effects of this drug include nausea (frequency: 19.8%), diarrhea (9.7%), abdominal 
distension (6.9%), headache (6.9%), and abdominal pain (5.2%) [40]. Recently, 
the mechanism of action of lubiprostone as a therapeutic drug for constipation was 
investigated in detail (see below.) Notably, a study based on a questionnaire regard-
ing QOL, work productivity, and lifestyle impairment found that lubiprostone 
improved both symptoms related to chronic constipation and the patients’ QOL 
[43]. In a phase 3 trial, Fukudo et al. found that long-term lubiprostone adminis-
tration was associated with an average increase in the average spontaneous bowel 
movement (SBM) number per week and an improved QOL among Japanese patients 
with chronic idiopathic constipation [44]. In a randomized, double-blind, placebo-
controlled trial of the effects of lubiprostone on chronic idiopathic constipation in 
diabetic patients, Christie et al. found that this drug reduced the colon transit time 
and increased the SBM number safely and effectively [45].
Parkinson’s disease: Parkinson’s disease is a very common neurodegenerative 
disorder characterized by motility disturbances. Constipation occurs very fre-
quently in affected patients and is a predictor of the onset of movement disorder. 
Constipation appears as a symptom prior to more obvious signs of parkinsonism 
before disappearance of dopamine cells in substantia nigra. Accordingly, clini-
cians should consider the early detection of a movement disorder when evaluating 
cases of constipation. In a double-blind RCT of the efficacy and tolerability of 
lubiprostone in patients with Parkinson’s disease with constipation, Ondo et al. 
concluded that the drug was well tolerated and effective when administered for a 
short duration [46].
Efficacy of lubiprostone for CKD: Mishima et al. demonstrated clearly that 
lubiprostone could inhibit an exacerbation of adenine-induced CKD by altering 
the intestinal environment or intestinal flora. That study suggested that in a patient 
with CKD, the intestinal tract acts as a conduit for uremic toxin excretion that is 
comparable with hemodialysis and urine. Lubiprostone may, therefore, be a novel 
therapeutic drug for CKD [47].
Protective effects on the small intestine and “leaky gut syndrome.” The small intes-
tine serves as a barrier for the selective transport of molecules in and out of the 
gastrointestinal tract. Failure of this barrier function renders the patient unable 
to absorb the nutrient for use as energy and can enable the transport of microbial 
pathogens and harmful chemical substances into the interior of the body. This state 
is known as the “leaky gut syndrome” and is thought to induce various diseases, 
including gastrointestinal diseases (e.g., inflammatory bowel disease), allergies, 
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diabetes, connective tissue diseases, and liver diseases [48]. Therefore, the preven-
tion of leaky gut syndrome would be therapeutically valuable.
No currently available therapeutic drug can improve abnormal intestinal tract 
permeability in humans. However, Moeser et al. revealed that lubiprostone not only 
promotes the secretion of intestinal fluid by activating ClC-2 channels but also 
protects and restores injured small intestinal mucosa [49]. The mechanism underly-
ing the restoration of tight junctions in the mucosa remains unknown, although the 
ClC-2 channel was found to play an important role in restoring the tight-junction 
structure and barrier function in a mouse model of colitis [48]. Furthermore, Kato 
et al. demonstrated that lubiprostone could improve intestinal permeability in 
humans [50]. Although these research findings require validation, lubiprostone 
appears to be a promising treatment for leaky gut syndrome.
Anti-inflammatory effect. Experimentally, lubiprostone was shown to prevent 
indomethacin-induced intestinal disease through a mechanism dependent on the 
prostaglandin EP4 receptor subtype in male Sprague-Dawley rats. This effect might 
suppress excessive intestinal motility and promote intestinal fluid secretion, while 
controlling bacterial invasion and inducible nitric-oxide synthase/tumor necrosis 
factor alpha expression, the main pathological events of intestinal disease. However, it 
is difficult to understand how the protective effect of lubiprostone would rely on the 
direct activation of the cystic fibrosis transmembrane regulator/ClC-2 channel [51].
Promotion of mucin secretion. Lubiprostone has been shown to promote mucin 
secretion in the small intestinal mucosa via a prostaglandin-like action and thus 
maintain digestive function [51]. Lubiprostone might also promote the intestinal 
transit of feces by providing lubrication and could thus improve the likelihood of 
comfortable defecation [52, 53].
Lubiprostone in clinic. A previous report indicated a correlation of Munchausen 
syndrome with the overuse of stimulant laxatives [54], which presents a chal-
lenge regarding dependence on these drugs. We, therefore, investigated whether 
lubiprostone administration would facilitate a reduction in the dose of a continu-
ously administered stimulant laxative. In real clinics, we have shown the successful 
reduction or cessation of the stimulant laxative (e.g., sodium picosulfate, senna) 
in more than 50% of cases (n = 21) within 6 months of administering lubiprostone 
(manuscript in preparation). Notably, no further medications were needed in these 
cases. These clinical experiences suggested us that the lubiprostone may be useful 
not only for the symptom itself but also for the reduction of stimulant laxatives 
leading to the safe and cost effective treatment of constipation.
7.2 Linaclotide
Linaclotide is a newly developed therapeutic drug for chronic constipation and 
constipation-predominant IBS. This drug is absorbed at low levels and has few 
adverse effects, of which the main complaint is diarrhea [55]. This peptide drug 
comprises 14 amino acids and acts by binding to the guanylate cyclase C (GC-C) 
receptor expressed on intestinal epithelial cells, which promotes the secretion of 
fluids into the intestinal lumen. The GC-C receptor is associated with bodily fluid 
and ionic homeostasis, bowel movements, and relief from afferent pain signaling 
and is thus considered a therapeutic target for chronic constipation and constipa-
tion-predominant IBS [56].
When compared with placebo, linaclotide yielded excellent results in terms 
of the reduction in abdominal pain and increase in complete SBMs at 12 weeks 
after the initial first administration [57]. Furthermore, linaclotide was associ-
ated with a significant increase in the average QOL score relative to placebo in a 
questionnaire-based survey [58]. A cost-effectiveness analysis study revealed that 
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the less expensive linaclotide yielded equivalent patient satisfaction to that achieved 
with lubiprostone [59]. As chronic constipation overlaps partially with constipa-
tion-predominant IBS, linaclotide may greatly expand the treatment options for 
constipation. Although linaclotide has been prescribed widely at our hospital at an 
appropriate once-daily dosage of 0.5 mg, we presume that many physicians may 
initiate this drug at a daily dosage of 0.25 mg to avoid adverse effects.
7.3 Elobixibat
Bile acids are synthesized from cholesterol in the liver and secreted to the 
duodenum, where they play an essential role in lipid digestion and absorption. 
Upon reaching the terminal ileum, bile acids are absorbed solely by the ileal bile 
acid transporter (IBAT) expressed only in the terminal ileum [60]. Here, 95% of 
the bile acids are reabsorbed through the portal system and are reconjugated and 
reexcreted into bile by hepatocytes in an enterohepatic cycle that occurs 2–15 times 
daily. Unabsorbed bile acids are transported to the colon, where they encourage 
the secretion of water into the large bowel lumen and thus promote large bowel 
movement [61, 62]. Accordingly, the administration of ursodeoxycholic acid or the 
occurrence of ileal diseases that enable the transport of excess amounts of bile acids 
to the large bowel can cause diarrhea [60].
The drug elobixibat specifically inhibits the IBAT required for bile acid reab-
sorption and is thus commercially available as the first IBAT inhibitor. Through its 
inhibitory actions, elobixibat increases the entry of bile acids into the large bowel 
and thus promotes evacuation. When administered orally, this drug is absorbed 
at low levels; accordingly, it has few adverse effects and is considered safe [63]. In 
Japan, elobixibat is administered orally at a once-daily dosage of 10 mg before a 
meal. However, the usage of this drug may vary among countries and should be 
confirmed carefully. To date, elobixibat has been used in only seven cases at our 
hospital in the short time since it has been licensed. Although only two patients 
have used this drug continuously for at least 2 months, all treated patients have 
achieved complete SBM. Elobixbat appears to act simultaneously as a stool softener 
and laxative stimulant. We expect that the use of this drug will increase.
7.4 Naldemedine
Naldemedine, a peripherally acting μ-opioid receptor antagonist, was developed 
as a therapeutic drug for opioid-induced constipation and is approved in the US 
and Japan [64]. This new class medication showed important therapeutic effect in 
improving opioid-induced constipation without reducing the efficacy of opioid 
drugs because it selectively targets the peripheral μ-opioid receptor as demonstrated 
in two-phase 3 trials [65, 66]. Therefore, although opioid-induced constipation 
has been initially treated with conventional laxatives, however, based on these 
evidences, naldemedine is expected to become a leading therapy for cases using 
opioids. Recently, we are switching to naldemedine to manage the constipation 
in cases using opioid, and approximately one-third of patients using opioids have 
been treated with naldemedine and showed the safe and effective bowel movement 
(manuscript in preparation).
8. Conclusion
To improve the QOL in the cases suffered with chronic constipation, the appro-
priate therapeutic intervention is essential. With the rise in the therapeutic options 
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and its real world data, and the objective assessment methods, its treatment is 
dramatically changing. It is obvious that the correct diagnosis excluding the emer-
gent situation is essential; however, the physicians need to update the information 
for these newly developed medicines useful for constipation and switch from the 
conventional agents for better QOL.
As the appropriate use of these new agents under various conditions remains 
uncertain, therefore, the accumulation of the clinical information, real-world data 
are necessary. For this purpose, this review overviewed the symptoms, diagnosis, 
and medicines available to date. We hope that these informations are useful for phy-
sicians treating patients and that various pathophysiological studies will elucidate 
the correct use of these new anticonstipation agents.
Furthermore, we hope that the development of a more ideal questionnaire 
will enable effective decisions regarding the most effective treatment for chronic 
constipation.
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